ImageneBio, Inc. (IMA): BVF group discloses 9.99% stake and large warrants

Rhea-AI Filing Summary

ImageneBio, Inc. is reported to have a significant shareholder group led by Biotechnology Value Fund entities and Mark N. Lampert. As of the close of business on June 30, 2026, these reporting persons collectively may be deemed to beneficially own 1,128,647 shares of ImageneBio common stock, or approximately 9.99% of the outstanding shares, including shares held in a managed account.

The group also holds pre-funded warrants exercisable for an aggregate of 528,947 shares at an exercise price of $0.001 per share. These warrants are exercisable at any time and do not expire, but a 9.99% beneficial ownership blocker currently limits exercise to 18,645 of those shares. The ownership percentages are based on 11,279,130 shares outstanding as of June 30, 2026, plus the exercisable warrant shares.

Key Figures

Collective beneficial ownership: 1,128,647 shares Ownership percentage: 9.99% Shares outstanding: 11,279,130 shares +5 more

8 metrics

Collective beneficial ownership 1,128,647 shares Shares that BVF entities and a managed account may be deemed to beneficially own as of June 30, 2026

Ownership percentage 9.99% Approximate percentage of ImageneBio common stock beneficially owned by BVF group, Partners, BVF Inc. and Mark N. Lampert

Shares outstanding 11,279,130 shares ImageneBio common shares outstanding as of June 30, 2026

Pre-funded warrants underlying shares 528,947 shares Aggregate shares of ImageneBio common stock underlying pre-funded warrants held by reporting persons and a managed account

Warrant exercise price $0.001 per share Exercise price of the pre-funded warrants for ImageneBio common stock

Exercisable warrant shares under blocker 18,645 shares Portion of the 528,947 warrant shares currently exercisable due to the 9.99% ownership blocker

BVF L.P. beneficial ownership 611,834 shares Shares beneficially owned by Biotechnology Value Fund, L.P., including some warrant shares and excluding others

BVF II L.P. beneficial ownership 433,269 shares Shares beneficially owned by Biotechnology Value Fund II, L.P.

Key Terms

Pre-Funded Warrants, Pre-Funded Warrants Blocker, beneficially owned, investment manager, +1 more

5 terms

Pre-Funded Warrants financial

"held pre-funded warrants (the "Pre-Funded Warrants") exercisable for an aggregate of 528,947 shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Pre-Funded Warrants Blocker financial

"would exceed 9.99% (the "Pre-Funded Warrants Blocker"). As of the close"

beneficially owned financial

"BVF beneficially owned 611,834 Shares, including 18,645 Shares underlying certain"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

investment manager financial

"Partners, as the investment manager of BVF, BVF2 and Trading Fund OS"

dispositive power financial

"Sole Dispositive Power 0.00 8 | Shared Dispositive Power 611,834.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

FAQ

What percentage of ImageneBio, Inc. (IMA) is held by the BVF reporting group?

The BVF reporting group may be deemed to beneficially own 1,128,647 shares of ImageneBio, Inc., representing approximately 9.99% of the outstanding common stock. This includes shares held across several BVF funds and a managed account.

How many ImageneBio (IMA) shares are outstanding according to this Schedule 13G/A?

The filing states that there were 11,279,130 shares of ImageneBio common stock outstanding as of June 30, 2026. Ownership percentages for the BVF entities are calculated using this share count plus certain exercisable warrant shares.

What pre-funded warrants in ImageneBio (IMA) does the BVF group hold?

The reporting persons and a managed account hold pre-funded warrants exercisable for an aggregate of 528,947 shares of ImageneBio common stock at an exercise price of $0.001 per share. These warrants are exercisable at any time and do not expire until fully exercised.

What is the 9.99% blocker on ImageneBio (IMA) pre-funded warrants held by BVF?

The pre-funded warrants include a 9.99% beneficial ownership blocker, preventing exercise if it would push the holder above 9.99% ownership. As of June 30, 2026, this limits exercise to 18,645 of the 528,947 underlying shares held by the reporting group.

How many ImageneBio (IMA) shares does Biotechnology Value Fund, L.P. specifically report?

Biotechnology Value Fund, L.P. beneficially owned 611,834 shares of ImageneBio as of June 30, 2026, including 18,645 shares underlying certain pre-funded warrants and excluding 257,441 warrant shares that are not currently exercisable due to the ownership blocker.

What is Mark N. Lampert’s reported beneficial ownership in ImageneBio (IMA)?

Mark N. Lampert may be deemed to beneficially own 1,128,647 shares of ImageneBio common stock, or approximately 9.99% of the outstanding shares, through his role as a director and officer of BVF Inc., subject to the disclaimer of beneficial ownership included in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:18 PM Accepted by SEC EDGAR 08/14/2026 - 04:08 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 7)

ImageneBio, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

45175G207

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45175G207

1

Names of Reporting Persons

BIOTECHNOLOGY VALUE FUND L P

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 611,834.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 611,834.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

611,834.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 45175G207

1

Names of Reporting Persons

BVF I GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 611,834.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 611,834.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

611,834.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 45175G207

1

Names of Reporting Persons

BIOTECHNOLOGY VALUE FUND II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 433,269.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 433,269.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

433,269.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 45175G207

1

Names of Reporting Persons

BVF II GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 433,269.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 433,269.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

433,269.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 45175G207

1

Names of Reporting Persons

Biotechnology Value Trading Fund OS LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 66,808.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 66,808.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

66,808.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.6 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 45175G207

1

Names of Reporting Persons

BVF Partners OS Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 66,808.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 66,808.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

66,808.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.6 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 45175G207

1

Names of Reporting Persons

BVF GP HOLDINGS LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,045,103.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,045,103.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,045,103.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 45175G207

1

Names of Reporting Persons

BVF PARTNERS L P/IL

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,128,647.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,128,647.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,128,647.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP Number(s): 45175G207

1

Names of Reporting Persons

BVF INC/IL

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,128,647.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,128,647.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,128,647.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 45175G207

1

Names of Reporting Persons

LAMPERT MARK N

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,128,647.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,128,647.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,128,647.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ImageneBio, Inc.
(b)	Address of issuer's principal executive offices: 12526 High Bluff Drive, Suite 345, San Diego, California 92130
Item 2.
(a)	Name of person filing: Biotechnology Value Fund, L.P. ("BVF") BVF I GP LLC ("BVF GP") Biotechnology Value Fund II, L.P. ("BVF2") BVF II GP LLC ("BVF2 GP") Biotechnology Value Trading Fund OS LP ("Trading Fund OS") BVF Partners OS Ltd. ("Partners OS") BVF GP Holdings LLC ("BVF GPH") BVF Partners L.P. ("Partners") BVF Inc. Mark N. Lampert ("Mr. Lampert") Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)	Address or principal business office or, if none, residence: Biotechnology Value Fund, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF I GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Fund II, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF II GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Trading Fund OS LP PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF Partners OS Ltd. PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF GP Holdings LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Partners L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Mark N. Lampert 44 Montgomery St., 40th Floor San Francisco, California 94104
(c)	Citizenship: Biotechnology Value Fund, L.P. Delaware BVF I GP LLC Delaware Biotechnology Value Fund II, L.P. Delaware BVF II GP LLC Delaware Biotechnology Value Trading Fund OS LP Cayman Islands BVF Partners OS Ltd. Cayman Islands BVF GP Holdings LLC Delaware BVF Partners L.P. Delaware BVF Inc. Delaware Mark N. Lampert United States
(d)	Title of class of securities: Common Stock, $0.001 par value
(e)	CUSIP No.: 45175G207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of the close of business on June 30, 2026, the Reporting Persons and a certain Partners managed account (the "Partners Managed Account") held pre-funded warrants (the "Pre-Funded Warrants") exercisable for an aggregate of 528,947 shares of the Issuer's Common Stock, $0.001 par value per share (the "Shares"). The Pre-Funded Warrants have an exercise price of $0.001 per Share, are exercisable at any time after original issuance, and will not expire until exercised in full. The Pre-Funded Warrants may not be exercised if the aggregate number of Shares beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% (the "Pre-Funded Warrants Blocker"). As of the close of business on June 30, 2026, the Pre-Funded Warrants Blocker limits the exercise of the Pre-Funded Warrants held by the Reporting Persons and the Partners Managed Account to 18,645 out of the 528,947 Shares underlying the Pre-Funded Warrants held by them. As of the close of business on June 30, 2026, (i) BVF beneficially owned 611,834 Shares, including 18,645 Shares underlying certain Pre-Funded Warrants held by it and excluding 257,441 Shares underlying certain Pre-Funded Warrants held by it, (ii) BVF2 beneficially owned 433,269 Shares, excluding 209,416 Shares underlying the Pre-Funded Warrants held by it, and (iii) Trading Fund OS beneficially owned 66,808 Shares, excluding 34,835 Shares underlying the Pre-Funded Warrants held by it. BVF GP, as the general partner of BVF, may be deemed to beneficially own the 611,834 Shares beneficially owned by BVF. BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 433,269 Shares beneficially owned by BVF2. Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 66,808 Shares beneficially owned by Trading Fund OS. BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 1,045,103 Shares beneficially owned in the aggregate by BVF and BVF2. Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 1,128,647 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, including 16,736 Shares held in the Partners Managed Account, which excludes 8,610 Shares underlying the Pre-Funded Warrants held in the Partners Managed Account. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 1,128,647 Shares beneficially owned by Partners. Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 1,128,647 Shares beneficially owned by BVF Inc. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
(b)	Percent of class: The following percentages are based upon a denominator that is the sum of: (i) 11,279,130 Shares outstanding as of June 30, 2026, as disclosed in the Issuer's Registration Statement on Form S-3 filed with the Securities and Exchange Commission on August 5, 2026 and (ii) 18,645 Shares issuable upon the exercise of certain Pre-Funded Warrants held by the Reporting Persons, as applicable. As of the close of business on June 30, 2026, (i) BVF beneficially owned approximately 5.4% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.8% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.4% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 3.8% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.3% of the outstanding Shares and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.99% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Cover Pages Items 5-9.
	(ii) Shared power to vote or to direct the vote: See Cover Pages Items 5-9.
	(iii) Sole power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
	(iv) Shared power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on April 5, 2021.
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BIOTECHNOLOGY VALUE FUND L P

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF I GP LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BIOTECHNOLOGY VALUE FUND II LP

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF II GP LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

Biotechnology Value Trading Fund OS LP

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF Partners OS Ltd.

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF GP HOLDINGS LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF PARTNERS L P/IL

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

BVF INC/IL

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	08/14/2026

LAMPERT MARK N

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert
Date:	08/14/2026